NeuroMetrix (NASDAQ: NURO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-21 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.140 | ||||||
REV | 2.302M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of NeuroMetrix (NASDAQ: NURO) through any online brokerage.
Other companies in NeuroMetrix’s space includes: ENDRA Life Sciences (NASDAQ:NDRA), Bluejay Diagnostics (NASDAQ:BJDX), Venus Concept (NASDAQ:VERO), Talis Biomedical (NASDAQ:TLIS) and Tivic Health Systems (NASDAQ:TIVC).
The latest price target for NeuroMetrix (NASDAQ: NURO) was reported by Rodman & Renshaw on Tuesday, June 28, 2016. The analyst firm set a price target for 4.50 expecting NURO to rise to within 12 months (a possible 21.62% upside). 0 analyst firms have reported ratings in the last year.
The stock price for NeuroMetrix (NASDAQ: NURO) is $3.7 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for NeuroMetrix.
NeuroMetrix’s Q2 earnings are confirmed for Thursday, July 21, 2022.
There is no upcoming split for NeuroMetrix.
NeuroMetrix is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.